Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $68.60, with 7.83 million shares of worth about $537.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -33.16% during that period and on Wednesday the price saw a loss of about -2.61%. Currently the company’s common shares owned by public are about 3.37B shares, out of which, 3.37B shares are available for trading.
Stock saw a price change of 0.59% in past 5 days and over the past one month there was a price change of 9.55%. Year-to-date (YTD), NVO shares are showing a performance of -20.25% which decreased to -49.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $57.00 but also hit the highest price of $148.15 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 9.59 million. The stock is currently trading 2.32% above its 20-day simple moving average (SMA20), while that difference is up 2.33% for SMA50 and it goes to -28.75% lower than SMA200. Novo Nordisk ADR (NYSE: NVO) currently have 3.37B outstanding shares and institutions hold larger chunk of about 9.71% of that.
The stock has a current market capitalization of $230.92B and its 3Y-monthly beta is at 0.65. PE ratio of stock for trailing 12 months is 20.35, while it has posted earnings per share of $3.37 in the same period. Its PEG reads 1.06 and has Quick Ratio of 0.56 while making debt-to-equity ratio of 0.86. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 3.08% while standing at 2.89% over the month.
Stock’s fiscal year EPS is expected to rise by 25.73% while it is estimated to increase by 18.77% in next year. EPS is likely to shrink at an annualized rate of 19.12% for next 5-years, compared to annual growth of 21.74% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on April 17, 2025 offering a Market perform rating for the stock and assigned a target price of $64 to it. Stock get a Mkt perform rating from Bernstein on January 06, 2025.
